Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
News
Publication of an independent equity research by Aurgalys
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
Quantum Genomics announces the appointment of international experts as members of its Scientific Advisory Board
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
Quantum Genomics receives financial aid from Bpifrance (France Public Innovation Bank) for its research program evaluating combinations of its new class of molecules with other anti-hypertensive compounds
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
Professor Pierre Corvol appointed Chairman of the Scientific Advisory Board of Quantum Genomics
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
Quantum Genomics disclosed the final results of phase I clinical trials for QGC001 during the joint Meeting of the European and International Societies of Hypertension (ESH-ISH) in Athens (Greece)
Quantum Genomics, (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing…
Quantum Genomics strengthens its management team by appointing Marc Karako, Chief Financial Officer, and Jean-Philippe Milon, Chief Operating Officer – 2014-05-14
Quantum Genomics, an innovative biopharmaceutical company developing new therapies for cardiovascular diseases (Alternext – FR0011648971 –…
Additional private placement of 240K€ : total fundraising increased to 3 650 K€ in 2014
Quantum Genomics, a biopharmaceutical research company developing new treatments in the field of cardiovascular diseases,…
Free Market – Alternext: Quantum Genomics passes a new milestone
Listed on the open market since the summer of 2009, Quantum Genomics has just transferred…
Quantum Genomics transfers its shares to Alternext Paris as of April 10, 2014, following a capital increase of €3.4 million
Quantum Genomics, a biopharmaceutical research company developing new treatments in the field of cardiovascular diseases,…